Cellino, a regenerative medicine company pioneering autonomous manufacturing systems for personalized cells, has been invited to speak at the Keystone Symposia conference, iPSCs: Progress, Opportunities, and Challenges, scheduled for January 26–29, 2026, in Kyoto, Japan. The event marks the 20th anniversary of the groundbreaking discovery of induced pluripotent stem cell (iPSC) technology, a milestone that has transformed fields ranging from developmental biology and disease modeling to drug discovery and cell-based therapies. The conference will bring together leading scientists, clinicians, and industry experts to discuss the evolution of iPSC applications, with a focus on clinical translation, next-generation cell therapies, organoid platforms, and emerging ethical challenges. A keynote address will be delivered by Nobel Laureate Dr. Shinya Yamanaka, co-organizer of the symposium and the scientist who first reprogrammed adult cells into pluripotent stem cells at Kyoto University, earning him the 2012 Nobel Prize in Physiology or Medicine. On Wednesday, January 28, Marinna Madrid, Ph.D., Co-Founder and Chief Product Officer of Cellino, will present in the session “Human iPSC-based Therapeutic Development I.” Her talk, titled “Creating an Industrial Revolution for Personalized Cell Therapies,” will address the critical bottleneck in autologous iPSC-based therapies: manufacturing scalability. Madrid will highlight how integrating automation, systems engineering, and precise process control can overcome current limitations and unlock the full potential of regenerative and longevity-focused treatments. “Personalized iPSC-based therapies hold enormous promise, but manufacturing has been the limiting factor,” said Dr. Madrid. “By rethinking cell production as an industrial-scale engineering challenge, we can make these therapies more reliable, scalable, and accessible. Japan has been a global leader in iPSC research and clinical translation for nearly two decades. It’s a privilege to contribute to this milestone event and help shape the future of regenerative medicine.” The symposium will be held in person in Kyoto, with on-demand access available for remote participants. It is supported by leading institutions across academia, biotechnology, and pharmaceuticals. About Cellino Cellino is building the industrial-scale manufacturing infrastructure needed to enable personalized regenerative medicine, from iPSC generation to tissue and organ replacement. The company’s platform leverages automation and precision engineering to produce patient-derived cells with consistent quality and scalability. Cellino has been granted an FDA Advanced Manufacturing Technology designation, underscoring its commitment to innovation in cell therapy production. For more information, visit www.cellinobio.com.